While bispecific antibodies tend to be well-tolerated for patients with multiple myeloma, there are still adverse effects clinicians should discuss with their patients. The use of bispecific ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with ...
The FDA granted elraglusib a rare pediatric disease designation for Ewing sarcoma based on findings from the 1/2 Actuate-1902 trial. The FDA granted a rare pediatric disease designation to elraglusib ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback